NPS Pharma and VIMAC Ventures locate at MaRS, a major new research and enterprise center in Toronto

TORONTO May 17, 2004 Salt Lake City-based NPS Pharmaceuticals and Boston-based VIMAC Ventures announced today that they plan to locate key business and research facilities to the new MaRS (Medical and Related Sciences) Discovery District biosciences research and commercialization hub in downtown Toronto. These firms have selected MaRS as the ideal global destination to pursue research and commercial opportunities in the fast-emerging medical and related technology fields.

MaRS Centre will become the primary location for NPS's research and development activities in Canada while VIMAC, a venture capital firm active in biosciences, will establish a business office in the center for the firm's VIMAC Milestone Medica Fund.

To date, 12 organizations have signed agreements to lease almost 600,000 square feet of the 700,000 square feet available in Phase One of MaRS Centre, including CMDF (Canadian Medical Discoveries Fund), the Hospital for Sick Children, MDS Inc. (MDS Sciex Division), RBC Technology Ventures Inc., RBC Financial Group, University Health Network and the Blueprint Initiative.

"With its proximity to some of the leading minds and institutions in Toronto's bioscience cluster, MaRS is the perfect site for our drug research and development work in Canada," says Dr. Hunter Jackson, Chairman, President and CEO of NPS. "Our presence at MaRS underscores our commitment to research and development in Canada and the importance of this new facility to our future business success."

NPS will initially move approximately 70 researchers into a wet lab facility at MaRS, with plans to add another 50 scientists over time. The company has been mining a wealth of research from the Toronto area for many years.

VIMAC chose MaRS to expand the firm's North American reach because it provides one of the most dynamic opportunities for investment in biosciences, according to Dana Ono, Managing Director, VIMAC Milestone Medica Fund.



Page: 1 2 3 4

Related biology news :

1. Warren Pharmaceuticals publishes results of preclinical evaluation
2. Pharmacogenomics could replace trial-and-error with science from the human genome
3. Cyclis Pharmaceuticals reports studies defining new mechanism for potential cancer therapies
4. Relapse or remission? Pharmacogenomics draws the fine line
5. Pharmaceutical smart bomb targets cancer cells
6. Final results of the two Zevalin pivotal trials in radioimmunotherapy for B cell Non-Hodgkins Lymphoma announced by IDEC Pharmaceuticals
7. Science and Amersham Pharmacia Biotech grand prize: "jumping DNA" discovery explains immune system evolution
8. Pharmaceutical and personal care products: What happens when they enter the environment - an emerging concern
9. Science and Amersham Pharmacia Biotech award Young Scientist Prize
10. Researchers, Regulators, Industry, Consumer Advocates Gather to Discuss Critical Issues Facing the Pharmaceutical Industry
11. Ribozyme Pharmaceuticals, Inc. Demonstrates Potent Activity Of A Ribozyme Targeted Against The Hepatitis C Virus

Post Your Comments:

(Date:1/20/2019)... ... January 16, 2019 , ... uBiome, the leader in ... that uses artificial intelligence (AI) and a data-centric approach to decentralize medicine using ... colitis. , People will Crohn’s or other chronic medical conditions join a relevant ...
(Date:1/14/2019)... ... 14, 2019 , ... CellMax Life , a diagnostics ... will present new findings at the ASCO Gastrointestinal Cancer Symposium in San Francisco ... from this study show CellMax Life’s blood test, based on its proprietary CMxTM ...
(Date:1/10/2019)... ... 2019 , ... A major goal for pharmaceutical companies has ... significantly more expensive in vivo studies in order to reduce costs and improve ... researchers have begun to adopt 3D cell culture models which have been shown ...
Breaking Biology News(10 mins):
(Date:1/30/2019)... ... January 30, 2019 , ... In ... tasting 5StarWines to promote and give recognition to producers whose work focuses entirely ... selection takes place in Verona, Italy, contemporaneously to the 5StarWines blind tasting organized ...
(Date:1/24/2019)... ... 22, 2019 , ... Controlled Contamination Services is pleased to announce three exciting ... these valuable new team members will support its growing operation across the US and ... scales its business. This addition will enable CCS to widen its reach and provide ...
(Date:1/24/2019)... ... January 22, 2019 , ... Outsourcing trials to contract ... of assumptions, and RFP creation and management generally requires manual effort. Additionally, each ... to oranges. These challenges can ultimately lead to study start delays and change ...
(Date:1/21/2019)... FRANKLIN, Wis. (PRWEB) , ... January 21, 2019 ... ... company, announced their newest product line, SporActiv™, for the industrial and institutional cleaning ... a variety of residential and commercial cleaning needs. Applications include odor control, floor ...
Breaking Biology Technology:
Cached News: